ArticleFrontiers in allergy2026
Eosinophilic cystitis refractory to multiple treatments with good response to benralizumab: case report.
Article in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Eosinophilic cystitis is a rare inflammatory bladder disorder characterized by eosinophilic infiltration of the bladder wall. It frequently mimics infectious, inflammatory, or malignant conditions, and its management remains challenging due to the lack of standardized treatment. Although corticosteroids are commonly used, many cases are refractory and may require invasive procedures such as cystectomy. We report a novel case of severe, treatment-refractory eosinophilic cystitis without peripheral eosinophilia that achieved sustained remission with benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, highlighting a promising therapeutic alternative. Case presentation: A 44-year-old male with a history of allergic rhinoconjunctivitis presented with severe daily macroscopic haematuria requiring multiple hospitalizations, suprapubic pain, urinary urgency, and dysuria causing significant sleep disturbance. Cystoscopy showed diffuse erythematous areas, and bladder biopsy confirmed acute eosinophilic infiltration. Other causes (neoplasia, infection, parasites) were excluded. The patient was refractory to multiple courses of antibiotics, antihistamines, and corticosteroids, with only transient improvement.Off-label treatment with subcutaneous benralizumab 30 mg every four weeks (later every eight weeks) was initiated. Oral corticosteroids were discontinued after one month. After more than one year of follow-up, the patient achieved complete resolution of haematuria and bladder tenesmus, with nocturnal urgency reduced to once nightly, resulting in marked improvement in quality of life. No adverse events were observed. Conclusions: This case demonstrates the efficacy and safety of benralizumab in refractory eosinophilic cystitis, even in the absence of peripheral eosinophilia. Anti-IL-5/IL-5R monoclonal antibodies may represent a valuable steroid-sparing and surgery-sparing therapeutic option for selected patients with refractory disease. Further studies are warranted to confirm these findings and define the role of biologic therapy in this rare condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.